Tadafumi Kato1,2, Jun Ishigooka3, Mari Miyajima4, Kei Watabe4, Tomohiro Fujimori4,5, Takahiro Masuda4, Teruhiko Higuchi6,7, Eduard Vieta8. 1. Department of Psychiatry, Juntendo University, Tokyo, Japan. 2. Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Japan. 3. Institute of CNS Pharmacology, Tokyo, Japan. 4. Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan. 5. Sunovion Pharmaceuticals Inc., Marlborough, USA. 6. Japan Depression Center, Tokyo, Japan. 7. The National Center of Neurology and Psychiatry, Kodaira, Japan. 8. Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
Abstract
AIM: Previous studies conducted primarily in the USA and Europe have demonstrated the efficacy and safety of lurasidone 20-120 mg/day for the treatment of bipolar I depression. The aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar I depression among patients from diverse ethnic backgrounds, including those from Japan. METHODS: Patients were randomly assigned to double-blind treatment for 6 weeks with lurasidone, 20-60 mg/day (n = 184) or 80-120 mg/day (n = 169), or placebo (n = 172). The primary end-point was change from baseline to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS:Lurasidone treatment significantly reduced mean MADRS total scores from baseline to Week 6 for the 20-60-mg/day group (-13.6; adjusted P = 0.007; effect size = 0.33), but not for the 80-120-mg/day group (-12.6; adjusted P = 0.057; effect size = 0.22) compared with placebo (-10.6). Treatment with lurasidone 20-60 mg/day also improved MADRS response rates, functional impairment, and anxiety symptoms. The most common adverse events associated with lurasidone were akathisia and nausea. Lurasidone treatments were associated with minimal changes in weight, lipids, and measures of glycemic control. CONCLUSION:Monotherapy with once daily doses of lurasidone 20-60 mg, but not 80-120 mg, significantly reduced depressive symptoms and improved functioning in patients with bipolar I depression. Results overall were consistent with previous studies, suggesting that lurasidone 20-60 mg/day is effective and safe in diverse ethnic populations, including Japanese.
RCT Entities:
AIM: Previous studies conducted primarily in the USA and Europe have demonstrated the efficacy and safety of lurasidone 20-120 mg/day for the treatment of bipolar I depression. The aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar I depression among patients from diverse ethnic backgrounds, including those from Japan. METHODS:Patients were randomly assigned to double-blind treatment for 6 weeks with lurasidone, 20-60 mg/day (n = 184) or 80-120 mg/day (n = 169), or placebo (n = 172). The primary end-point was change from baseline to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS:Lurasidone treatment significantly reduced mean MADRS total scores from baseline to Week 6 for the 20-60-mg/day group (-13.6; adjusted P = 0.007; effect size = 0.33), but not for the 80-120-mg/day group (-12.6; adjusted P = 0.057; effect size = 0.22) compared with placebo (-10.6). Treatment with lurasidone 20-60 mg/day also improved MADRS response rates, functional impairment, and anxiety symptoms. The most common adverse events associated with lurasidone were akathisia and nausea. Lurasidone treatments were associated with minimal changes in weight, lipids, and measures of glycemic control. CONCLUSION: Monotherapy with once daily doses of lurasidone 20-60 mg, but not 80-120 mg, significantly reduced depressive symptoms and improved functioning in patients with bipolar I depression. Results overall were consistent with previous studies, suggesting that lurasidone 20-60 mg/day is effective and safe in diverse ethnic populations, including Japanese.
Authors: Antony Loebel; Josephine Cucchiaro; Robert Silva; Hans Kroger; Jay Hsu; Kaushik Sarma; Gary Sachs Journal: Am J Psychiatry Date: 2014-02 Impact factor: 18.112
Authors: Lindsay N Cates; Amanda J Roberts; Salvador Huitron-Resendiz; Peter B Hedlund Journal: Neuropharmacology Date: 2013-02-13 Impact factor: 5.250
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Jack Maser; David A Solomon; Andrew C Leon; John A Rice; Martin B Keller Journal: Arch Gen Psychiatry Date: 2002-06
Authors: Kathleen R Merikangas; Robert Jin; Jian-Ping He; Ronald C Kessler; Sing Lee; Nancy A Sampson; Maria Carmen Viana; Laura Helena Andrade; Chiyi Hu; Elie G Karam; Maria Ladea; Maria Elena Medina-Mora; Yutaka Ono; Jose Posada-Villa; Rajesh Sagar; J Elisabeth Wells; Zahari Zarkov Journal: Arch Gen Psychiatry Date: 2011-03
Authors: Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr Journal: PLoS One Date: 2014-09-25 Impact factor: 3.240